1-20 of 26
risk reduction
Close
Sort by
Journal Articles

Lowering the boom on lower-risk myelodysplastic syndromes

Mikkael A. Sekeres, Bhumika J. Patel
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 367–372.
https://doi.org/10.1182/hematology.2019000040
Published: 2019
Journal Articles

The MDS genomics-prognosis symbiosis

Aziz Nazha
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 270–276.
https://doi.org/10.1182/asheducation-2018.1.270
Published: 2018
Journal Articles

We do still transplant CML, don’t we?

Charles F. Craddock
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 177–184.
https://doi.org/10.1182/asheducation-2018.1.177
Published: 2018
Journal Articles

Current treatment algorithm for the management of lower-risk MDS

Aristoteles Giagounidis
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 453–459.
https://doi.org/10.1182/asheducation-2017.1.453
Published: 2017
Journal Articles

How should we sequence and combine novel therapies in CLL?

Matthew S. Davids
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 346–353.
https://doi.org/10.1182/asheducation-2017.1.346
Published: 2017
Journal Articles

Follicular lymphoma: are we ready for a risk-adapted approach?

Brad S. Kahl
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 358–364.
https://doi.org/10.1182/asheducation-2017.1.358
Published: 2017
Journal Articles

Treatment of low-risk myelodysplastic syndromes

Valeria Santini
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 462–469.
https://doi.org/10.1182/asheducation-2016.1.462
Published: 2016
Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.
https://doi.org/10.1182/asheducation-2015.1.308
Published: 2015
Journal Articles

Venous clot lysis and stenting

Suresh Vedantham
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 210–214.
https://doi.org/10.1182/asheducation-2015.1.210
Published: 2015
Journal Articles

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres, Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 82–89.
https://doi.org/10.1182/asheducation-2014.1.82
Published: 2014
Journal Articles

Balancing cure and long-term risks in acute lymphoblastic leukemia

Lewis B. Silverman
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 190–197.
https://doi.org/10.1182/asheducation-2014.1.190
Published: 2014
Journal Articles

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Andrea K. Ng
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 488–494.
https://doi.org/10.1182/asheducation-2014.1.488
Published: 2014
Journal Articles

Pharmacological methods to reduce disease recurrence

Charles Craddock
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 63–69.
https://doi.org/10.1182/asheducation-2013.1.63
Published: 2013
Journal Articles

Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program. 2012;2012: 65–73 .

Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 692.
https://doi.org/10.1182/asheducation.V2013.1.692.3851497a
Published: 2013
Journal Articles

Treatment of acute myeloid leukemia: are we making progress?

Alan K. Burnett
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 1–6.
https://doi.org/10.1182/asheducation.V2012.1.1.3797038
Published: 2012
Journal Articles

Novel therapeutic strategies: hypomethylating agents and beyond

Valeria Santini
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 65–73.
https://doi.org/10.1182/asheducation.V2012.1.65.3806843
Published: 2012
Journal Articles

Immunomodulating Drugs in Myelodysplastic Syndromes

Lionel Adès, Pierre Fenaux
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 556–560.
https://doi.org/10.1182/asheducation-2011.1.556
Published: 2011
Journal Articles

How I Diagnose and Manage HIT

Theodore E. Warkentin
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 143–149.
https://doi.org/10.1182/asheducation-2011.1.143
Published: 2011
Journal Articles

How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes

William Blum
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 314–321.
https://doi.org/10.1182/asheducation-2010.1.314
Published: 2010
Journal Articles

ASH evidence-based guidelines: statins in the prevention of venous thromboembolism

Natalie S. Evans, David Green
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 273–274.
https://doi.org/10.1182/asheducation-2009.1.273
Published: 2009